Atrium Innovations (formerly Atrium Biotechnologies) believes you are what you eat. Or rather, you are what you take! The company manufactures and markets more than 1,300 vitamins, minerals, and nutritional supplements geared toward alternative health consumers. Its Pure Encapsulations line of vitamin and herbal extract capsules are a premium brand of natural hypoallergenic products. The company sells products to health care professionals in more than 35 countries, primarily in North America and Europe, through its direct sales and marketing network.

Cambrex Corporation was founded in 1981 and is based in East Rutherford, New Jersey. Cambrex Corporation, a life sciences company, provides products and services to develop and commercialize active pharmaceutical ingredients and advanced intermediates. Its products include active pharmaceutical ingredients and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products, and other custom chemicals derived from organic chemistry. The company sells its products through direct sales and independent agents to pharmaceutical and generic drug companies worldwide.

Rosemont Pharmaceuticals keeps the medicine flowing. The drugmaker specializes in generic oral liquid formulations of drugs for patients who have difficulty swallowing pills and capsules, oftentimes elderly patients or young children. It makes more than 90 licensed products under its own brand -- including antibiotics, cardiovascular treatments, analgesics, and corticosteroids -- and distributes them primarily to hospitals, primary care centers, and pharmacies in the UK. It also makes custom liquid formulations of unlicensed drugs (called "Specials") and offers contract manufacturing services. In 2006 Close Brothers backed a management buy-out of Rosemont, which had been a subsidiary of Savient Pharmaceuticals.

AERES Biomedical Ltd. company was founded in 1999. AERES Biomedical develops therapeutic antibodies. The biopharmaceutical research company has developed more than 20 antibody candidates though collaborative partnerships with other biotech and pharmaceutical companies, many of which are in clinical trial stages. ABC-48 (an antibody for the treatment of deep vein thrombosis) and ABC-120 (an antibody for treating malaria) are two of the company's top candiates. AERES' products target debilitating and life-threatening illnesses, such as infectious, inflamatory, and cardiovascular diseases.

Qiagen N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands. Qiagen N.V. provides technologies and products for preanalytical sample preparation and linked molecular assay solutions worldwide. Its sample technologies are used to collect, stabilize, isolate, and purify deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteins from blood, bone, and tissue samples; and assay technologies are used to make specific target biomolecules, such as the DNA of a specific virus for subsequent detection and analysis. The company offers sample and assay consumable products that are used in plasmid, DNA purification; RNA purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. It also provides PCR assays, which allow PCR-based detection of viral, bacterial and parasite, human, and animal pathogens, as well as pharmacogenomic genotyping; and various other products for research in the areas of epigenetics, gene expression, micro RNA, proteomics, RNAi, and applied testing and molecular diagnostics. In addition, the company offers automated systems that provide walk-away automation of sample and assay technologies in low, medium, or high throughput scale, as well as reaction set-up and other laboratory tasks; QIAcube, which allows users in research in life sciences, applied testing, and molecular diagnostic to automate the processing of the company's consumable products; and instruments to OEM partners. Further, it provides custom services, such as whole genome amplification services, DNA sequencing, and non-cGMP DNA production on a contract basis; and sells and/or licenses technology. The company serves researchers at pharmaceutical and biotechnology companies, academic institutions, and government and private laboratories.

Millennium Pharmaceuticals wants to be "the" drug company for the new millennium. Its cancer drug Velcade is approved as a treatment for multiple myeloma (a type of blood cancer) and Mantle Cell Lymphoma (or MCL, an aggressive form of non-Hodgkin's lymphoma). The company has more than a dozen other candidates in the pipeline, most of them cancer-related. Millennium's oncology-focused sales force, in partnership with Johnson & Johnson subsidiary Ortho Biotech, sells the drug in the US; Ortho Biotech is responsible for sales in Europe and in other countries where Velcade is approved (except Japan, which is covered by Janssen). Takeda Pharmaceutical acquired Millennium Pharmaceuticals for $8.8 billion in 2008.

Pharming Group N.V. is a Netherlands-based biotechnology company. The Company has facilities both in the Netherlands and the United States. Pharming develops products for the treatment of diseases with significant medical needs, including genetic disorders, diseases associated with the immune system, ageing diseases, and nutritional products. The Company’s technologies include platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of DNA repair via its subsidiary DNage BV. Pharming products under development are divided into three categories: biopharmaceuticals, biomaterials, and bio-nutritionals. Products in the most advanced stage of development and closest to commercialization are Rhucin and human lactoferrin for use in food products. Pharming has several partnerships and collaborations with, inter alia, AgResearch, US Army, Aslan and Schering-Plough.

Spherotech, Inc. company was founded in 1992. pherotech is very particular about its business. Spherotech company manufactures microparticles for the drug and medical device industries. Its product offerings include ferromagnetic, fluorescent, latex, paramagnetic, and various colored microparticles. Spherotech's products are used in applications such as fluorescence and enzyme immunoassay.

Generex Biotechnology Corporation company was founded in 1983 and is based in Toronto, Canada. Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company's products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as an aid for dieters. Generex Biotechnology Corporation's under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; morphine and fentanyl products for breakthrough and postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S for the development of a metformin medicinal chewing gum.

Synteract, Inc. company has overseen hundreds of projects for clients that include biotechnology and pharmaceutical companies, as well as medical device makers. On top of research services, Synteract offers clients proprietary and customizable software solutions for managing research and trial data. The company's expertise covers a wide range of health issues, including oncology, HIV/AIDS, ophthalmology, and gastrointestinal disorders. Founded in 1995, Synteract maintains offices in San Diego, Philadelphia, and North Carolina.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.